entertainment -WSS

entertainment

author：entertainment 2025-09-30 00:49:10 - browse：3493

Red blood cells flow in an artery biotech — coverage from STAT — Adobe

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients.

Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen Pharmaceuticals.

The treatment, injected monthly, also reduced the risk of major bleeding events by 74% and gastrointestinal bleeding by 93%, according to Phase 2 results presented here Sunday at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Medicare Advantage enrollment hits roughly 33.4 million

hotspot

leisure time

WSS

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

RSV vaccines may be linked to small increased risk of developing GBS

Flu vaccine offering decent levels of protection this winter, new data show

Flu vaccine offering decent levels of protection this winter, new data show

Pfizer highlights cancer drugs it thinks could reignite investor interest

FDA does about

focus

entertainment

Wikipedia

How one medical school became remarkably diverse

Medical device lobby: We're tired of waiting on Medicare coverage

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

New air purifier tech could be key to improving indoor air quality

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

BioMarin wins approval for gene therapy to treat hemophilia A

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

hotspot

FDA does about

House looks to weaken Medicare negotiation

International team creates first chimeric human

House looks to weaken Medicare negotiation

House looks to weaken Medicare negotiation

Covid isolation guidance eased by the CDC

hotspot

focus

leisure time

explore